The four most important motor symptoms of Parkinson's disease (PD), the second most prevalent chronic
neurodegenerative disease, are tremor, bradykinesia, rigidity, and postural instability. As the disease progresses,
non-motor symptoms like cognitive impairment, aberrant behavior, and sleep difficulties could appear. The loss of
dopaminergic neurons in the substantia nigra pars compacta, a reduction in striatal dopamine, and the development of
Lewy bodies—abnormal protein clumps within neurons—are pathological features of PD.
Key Factors Important Targets Related Products
Key Factors
After years of learning, scientists have made considerable progress toward understanding the pathophysiology of PD,
however the disease's cause is still unknown. Monogenic PD is shown to be caused by mutations in several genes, and
new loci linked to sporadic disease have been revealed using GWAS. Mutations in six genes (SNCA, LRRK2, PRKN, DJ1,
PINK1, and ATP13A2) have been associated with PD. Loss-of-function mutations in GBA and polymorphisms in three
genes—MAPT, LRRK2, and SNCA—are additional risk factors. In addition to genetics, protein aggregation and
misfolding, oxidative stress, mitochondrial dysfunction, and neuroinflammation are all linked to the causes of PD.
Environmental factors, such as mitochondrial toxicants, heavy metals that can cause oxidative stress and
neurotransmission impairment, air pollution, or traumatic brain injury, are major risk factors for PD.
Fig.1 Intracellular α-synuclein homeostasis is sustained by the
lysosomal autophagy and ubiquitin–proteasome pathways1.
Important Targets Related to PD
Antibodies have excellent specificity and affinity, making them valuable tools for researchers exploring the
pathophysiology of PD. Creative Biolabs provides a wide range of application-proven antibodies for
researching proteins related to Parkinson's disease.
PARK7 PRKN ATP13A2 FBXO7 SLC6A3 SYNJ1 VPS35
Cat. No
|
Product Name
|
Host
|
Application
|
NAB2010178LS
|
NeuroMab™ Mouse Anti-Human PARK7 / DJ1 Monoclonal Antibody (CBP2257)
|
Monoclonal
|
WB; IHC-P
|
NPP2011ZP60
|
Human PARK7 Antibody Pair
|
Monoclonal
|
ELISA
|
NAB-0720-Z5694
|
Mouse Anti-PARK7 Monoclonal Antibody (CBP3109)
|
Monoclonal
|
FC; IHC-Fr; ICC; IF; WB; ICC; IHC-Fr
|
NAB-0720-Z5695
|
Rabbit Anti-PARK7 Monoclonal Antibody (CBP3110)
|
Monoclonal
|
WB; IHC-P; ICC; FC
|
NAB2105128SL
|
NeuroMab™ Mouse Anti-Human PARK7 (CBP5652)
|
Monoclonal
|
ELISA; WB
|
NAB2007FY442
|
Human Anti-DJ-1 (CBP1952)
|
Monoclonal
|
ELISA; WB
|
See all PARK7 antibodies
Cat. No
|
Product Name
|
Host
|
Application
|
NRZP-0822-ZP881
|
NeuroMab™ Anti-Parkin Antibody, Clone N10976P (CBP9238)
|
Monoclonal
|
WB; FC; ICC; IF; IHC; IHC-P; IP
|
NAB201284LS
|
Mouse Anti-Human PARK2 Monoclonal Antibody (CBP3727)
|
Monoclonal
|
WB
|
NAB2010475LS
|
Mouse Anti-Parkin Monoclonal Antibody (CBP2406)
|
Monoclonal
|
WB; ICC; IHC-P
|
NPP2011ZP50
|
Human Parkin Antibody Pair Kit
|
|
ELISA
|
See all PRKN antibodies
Cat. No
|
Product Name
|
Host
|
Application
|
NAB-0720-Z2246
|
NeuroMab™ Rabbit Anti-SLC6A3 Monoclonal Antibody (CBP577)
|
Monoclonal
|
WB; IHC-P; IHC-Fr; IP
|
NAB-0720-Z2265
|
NeuroMab™ Mouse Anti-SLC6A3 Monoclonal Antibody (CBP592)
|
Monoclonal
|
WB; IHC-P
|
NAB-0720-Z2266
|
Rat Anti-SLC6A3 Monoclonal Antibody (CBP593)
|
Monoclonal
|
IHC-P
|
NRZP-1222-ZP785
|
NeuroMab™ Anti-Dopamine transporter Antibody, Clone 9D5
|
Monoclonal
|
In Vitro
|
NRZP-0822-ZP686
|
NeuroMab™ Anti-SLC6A3/DAT1 Antibody, Clone N27103P (CBP9162)
|
Monoclonal
|
WB; ELISA; ICC; IF; IHC; IHC-P; IP
|
See all SLC6A3 antibodies
Cat. No
|
Product Name
|
Host
|
Application
|
NAB-0720-Z2263
|
Mouse Anti-SYNJ1 Monoclonal Antibody (CBP590)
|
Monoclonal
|
ICC; IF; WB; IHC-Fr; IP
|
NAB2109P317
|
NeuroMab™ Mouse Anti-Rat SYNJ1 Monoclonal Antibody (CBP6957)
|
Monoclonal
|
WB; IHC
|
See all SYNJ1 antibodies
Cat. No
|
Product Name
|
Host
|
Application
|
NAB2007FY752
|
NeuroMab™ Mouse Anti-VPS35 Monoclonal Antibody (CBP2095)
|
Monoclonal
|
WB; IF; IP
|
NAB2007FY753
|
Mouse Anti-VPS35 Monoclonal Antibody (CBP2096)
|
Monoclonal
|
WB; IF; IP
|
NAB2007FY754
|
NeuroMab™ Rabbit Anti-VPS35 Monoclonal Antibody (CBP2097)
|
Monoclonal
|
WB; IP
|
NAB2007FY755
|
Mouse Anti-VPS35 Monoclonal Antibody (CBP2098)
|
Monoclonal
|
WB; IF; IP
|
NAB2007FY756
|
NeuroMab™ Mouse Anti-VPS35 Monoclonal Antibody (CBP2099)
|
Monoclonal
|
WB; IF; IP
|
See all VPS35 antibodies
If you have a query about PD-related antibodies, please click on the related products below or contact us directly and we will get back to you within 24 hours.
Reference
-
Dong-Chen, Xu, et al. "Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic
interventions." Signal transduction and targeted therapy 8.1 (2023): 73.
For Research Use Only. Not For Clinical Use.